300685 艾德生物
已收盘 06-05 15:00:00
资讯
新帖
简况
《21健讯Daily》|翰森制药减重新药申报上市；艾德生物复牌
21世纪经济报道 · 06-05 08:02
《21健讯Daily》|翰森制药减重新药申报上市；艾德生物复牌
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
智通财经网 · 06-04 19:53
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
艾德生物(300685.SZ)：筹划公司控制权变更事项 继续停牌
智通财经 · 06-02
艾德生物(300685.SZ)：筹划公司控制权变更事项 继续停牌
艾德生物(300685.SZ)筹划公司控制权变更事项 6月1日起停牌
智通财经 · 05-31
艾德生物(300685.SZ)筹划公司控制权变更事项 6月1日起停牌
艾德生物(300685.SZ)：“人类微卫星不稳定性(MSI)检测试剂盒(荧光PCR熔解曲线法)”获得医疗器械注册证
智通财经 · 05-20
艾德生物(300685.SZ)：“人类微卫星不稳定性(MSI)检测试剂盒(荧光PCR熔解曲线法)”获得医疗器械注册证
艾德生物(300685.SZ)发布一季度业绩，归母净利润8515.69万元，下降5.87%
智通财经 · 04-27
艾德生物(300685.SZ)发布一季度业绩，归母净利润8515.69万元，下降5.87%
艾德生物(300685.SZ)发布2025年度业绩，归母净利润3.61亿元，增长41.74%
智通财经 · 04-15
艾德生物(300685.SZ)发布2025年度业绩，归母净利润3.61亿元，增长41.74%
艾德生物(300685.SZ)：AmoyDx ® PIK3CA基因突变检测试剂盒在日本获批
智通财经 · 03-23
艾德生物(300685.SZ)：AmoyDx ® PIK3CA基因突变检测试剂盒在日本获批
艾德生物(300685.SZ)2025年度归母净利润3.58亿元 同比增长40.42%
智通财经 · 03-12
艾德生物(300685.SZ)2025年度归母净利润3.58亿元 同比增长40.42%
艾德生物：目前生产经营活动正常
证券日报网 · 2025-12-08
艾德生物：目前生产经营活动正常
艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份
智通财经 · 2025-02-25
艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份
【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。
金融界 · 2025-02-20
【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。
艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元
智通财经 · 2025-02-06
艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元
艾德生物(300685.SZ)获得两项医疗器械注册证
智通财经 · 2025-01-13
艾德生物(300685.SZ)获得两项医疗器械注册证
一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%
金融界 · 2024-12-29
一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%
加载更多
公司概况
公司名称：
厦门艾德生物医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2017-08-02
主营业务：
厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服务及药物临床研究服务。公司的主要产品是检测试剂、检测服务、药物临床研究服务。凭借卓越的研发实力，公司荣获“国家企业技术中心”、“制造业单项冠军企业”、“博士后科研工作站”、“专精特新小巨人企业”等资质和荣誉，研发团队荣膺“全国工人先锋号”、研发骨干荣获“全国劳动模范”光荣称号，研发成果获评“国家科技进步二等奖”、“国家专利银奖”、“教育部科技进步一等奖”等，充分彰显了公司在行业内的技术领先地位。
发行价格：
13.86
{"stockData":{"symbol":"300685","market":"SZ","secType":"STK","nameCN":"艾德生物","latestPrice":19.9,"timestamp":1780643004000,"preClose":20.41,"halted":0,"volume":27674152,"delay":0,"changeRate":-0.025,"floatShares":390000000,"shares":390000000,"eps":0.9125,"marketStatus":"已收盘","change":-0.51,"latestTime":"06-05 15:00:00","open":21.41,"high":21.52,"low":19.38,"amount":558000000,"amplitude":0.1049,"askPrice":19.9,"askSize":96,"bidPrice":19.89,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.9125,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":20.41,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":22.45,"lowLimit":18.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":390105169,"isCdr":false,"pbRate":3.87,"roa":"--","peRate":21.808219,"roe":"4.14%","epsLYR":0.91,"committee":0.199301,"marketValue":7763000000,"turnoverRate":0.071,"status":1,"floatMarketCap":7752000000},"requestUrl":"/m/hq/s/300685","defaultTab":"news","newsList":[{"id":"2641939531","title":"《21健讯Daily》|翰森制药减重新药申报上市；艾德生物复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2641939531","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641939531?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:02","pubTimestamp":1780617724,"startTime":"0","endTime":"0","summary":"政策动向世卫组织总干事呼吁建立长期医疗防御机制应对埃博拉疫情6月3日，世界卫生组织总干事谭德塞在当天的新闻发布会上强调，控制埃博拉疫情只是时间问题，但真正的成功应在于预防未来的疫情。谭德塞表示，世卫组织在全力应对当前疫情的同时，将致力于协助当地政府建设和完善长期的医疗与人道主义服务体系，打破“头痛医头”的循环。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606053760994263.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606053760994263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK1191","LU2460026573.USD","BK0042","IE0005HP3H50.USD","03692","300685","BK0239","BK1583","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159152","title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159152","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640159152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:53","pubTimestamp":1780574025,"startTime":"0","endTime":"0","summary":"本次权益变动完成后，国药集团(北京)科技创新研究院有限公司将成为公司控股股东，公司实际控制人将变更为中国医药集团有限公司。公司股票于2026年6月5日开市起复牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0082","LU2460026573.USD","BK0175","IE0005HP3H50.USD","BK0185","BK0028","BK0010","300685","BK0042","BK0239","BK0188","600056","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640192869","title":"艾德生物(300685.SZ)：筹划公司控制权变更事项 继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640192869","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640192869?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:35","pubTimestamp":1780392904,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司控股股东前瞻投资(香港)有限公司正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实际控制人发生变更。公司股票已于2026年6月1日(星期一)开市起停牌。截至公告日，相关各方正在积极推进上述事项的工作，公司预计无法在2026年6月3日(星期三)开市起复牌。鉴于该事项存在重大不确定性，为维护投资者利益，避免对公司股价造成重大影响，公司股票自2026年6月3日(星期三)开市起继续停牌，预计继续停牌时间不超过3个交易日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685","IE0005HP3H50.USD","LU2460026573.USD","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639360063","title":"艾德生物(300685.SZ)筹划公司控制权变更事项 6月1日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2639360063","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639360063?lang=zh_cn&edition=full","pubTime":"2026-05-31 16:37","pubTimestamp":1780216631,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司控股股东前瞻投资(香港)有限公司正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券交易所申请，公司股票自2026年6月1日(星期一)开市起停牌，预计停牌时间不超过2个交易日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"艾德生物(300685.SZ)筹划公司控制权变更事项 6月1日起停牌","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","300685","IE0005HP3H50.USD","BK0239","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817926","title":"艾德生物(300685.SZ)：“人类微卫星不稳定性(MSI)检测试剂盒(荧光PCR熔解曲线法)”获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817926","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636817926?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:53","pubTimestamp":1779267222,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司于近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，该产品为：“人类微卫星不稳定性(MSI)检测试剂盒(荧光PCR熔解曲线法)”。该产品用于体外定性检测结直肠癌患者肿瘤组织FFPE样本中的微卫星位点(ACVR2A、PRR5-ARHGAP8、EIF4E3、IFT140、RBM14-RBM4、UBAC2)。根据发生序列长度变化的微卫星位点数量，将结直肠癌分为微卫星高度不稳定型(MSI-H)与非微卫星高度不稳定型(MSS/MSI-L)两种微卫星状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2473716301.USD","BK4020","159883","LU2247934214.USD","LU1923622291.USD","LU2106854487.HKD","LU1992135399.USD","LU2506952097.USD","LU2272731600.USD","BK4585","IE0034235188.USD","IE00B775SV38.USD","LU1917777945.USD","LU2065169927.USD","LU2322448957.HKD","LU2125909916.SGD","LU0950375773.USD","LU2065171402.SGD","LU2506952170.USD","LU0823417653.USD","LU0823417737.USD","LU1992135472.HKD","LU2460026573.USD","MSI","BK1100","LU2023250843.SGD","LU2322448791.USD","LU0354030511.USD","09996","BK4588","IE00B3S45H60.SGD","LU0354030438.USD","IE0005HP3H50.USD","LU1974910355.USD","LU0107464264.USD","LU2272731782.SGD","LU2065170008.USD","LU2272731865.HKD","300685","LU2065171311.SGD","BK1583","BK1574","BK0042","LU2506951875.HKD","LU2506951958.HKD","PCR","LU2023250504.SGD","BK0239","LU2125909759.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630318813","title":"艾德生物(300685.SZ)发布一季度业绩，归母净利润8515.69万元，下降5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630318813","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630318813?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:37","pubTimestamp":1777300624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布2026年第一季度报告，该公司营业收入为2.6亿元，同比减少4.32%。归属于上市公司股东的净利润为8515.69万元，同比减少5.87%。归属于上市公司股东的扣除非经常性损益的净利润为8275.56万元，同比减少5.12%。基本每股收益为0.22元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627285265","title":"艾德生物(300685.SZ)发布2025年度业绩，归母净利润3.61亿元，增长41.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285265","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627285265?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:41","pubTimestamp":1776249666,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物 发布2025年年度报告，该公司营业收入为11.98亿元，同比增长8.01%。归属于上市公司股东的净利润为3.61亿元，同比增长41.74%。基本每股收益为0.91元。此外，拟向全体股东每10股派发现金红利4.5元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)发布2025年度业绩，归母净利润3.61亿元，增长41.74%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621860729","title":"艾德生物(300685.SZ)：AmoyDx ® PIK3CA基因突变检测试剂盒在日本获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2621860729","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621860729?lang=zh_cn&edition=full","pubTime":"2026-03-23 11:46","pubTimestamp":1774237584,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司自主研发的产品AmoyDx ® PIK3CA基因突变检测试剂盒于近日获得日本厚生劳动省批准上市。该产品检测结果准确、成功率高，性能稳定，样本需求量少且报告出具速度快，是海和药物的新型PI3Kα选择性抑制剂甲磺酸瑞索利塞片的伴随诊断试剂。本次获批，进一步丰富了公司肿瘤伴随诊断产品线，有利于增强公司海外市场竞争力，提升公司市场拓展能力，对公司未来的发展将产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)：AmoyDx ® PIK3CA基因突变检测试剂盒在日本获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU2460026573.USD","BK0042","IE0005HP3H50.USD","300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618631139","title":"艾德生物(300685.SZ)2025年度归母净利润3.58亿元 同比增长40.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618631139","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618631139?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:22","pubTimestamp":1773314522,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布2025年度业绩快报，报告期内，公司实现营业收入11.98亿元，同比增长8.00%，实现归属于上市公司股东的净利润3.58亿元，同比增长40.42%。在行业整体承压的背景下，公司持续夯实内部管理基础，组织架构优化成效显现;依托合规、创新经营优势，检测试剂业务保持良好增长态势，多项产品获批上市，盈利能力持续提升，展现出强劲的增长韧性;在此基础上，公司有序推进国际化布局调整，深化药企合作，加快构建精准诊疗生态，为未来实现长期稳健发展奠定坚实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)2025年度归母净利润3.58亿元 同比增长40.42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589433073","title":"艾德生物：目前生产经营活动正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2589433073","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589433073?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:39","pubTimestamp":1765193940,"startTime":"0","endTime":"0","summary":"证券日报网讯12月8日，艾德生物在互动平台回答投资者提问时表示，公司目前生产经营活动正常。BD部门将持续推进与包括礼来在内的国内外知名药企在伴随诊断领域的合作。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-08/doc-inhacacc1597971.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-08/doc-inhacacc1597971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2460026573.USD","IE0005HP3H50.USD","BK0239","BK0042","300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514528069","title":"艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2514528069","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514528069?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:09","pubTimestamp":1740478144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)公告，公司回购股份方案已实施完毕，截至2025年2月25日，公司以集中竞价交易方式累计回购公司股份537.48万股，占公司当前总股本的比例为1.35%，成交总金额为1.01亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","300685","IE0005HP3H50.USD","BK0239","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512349084","title":"【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512349084","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512349084?lang=zh_cn&edition=full","pubTime":"2025-02-20 15:56","pubTimestamp":1740038163,"startTime":"0","endTime":"0","summary":"金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20155648278395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","159883","BK1161","LU1169590202.USD","09939","BK4023","LU2460026573.USD","BK1100","09997","09996","LU1169589451.USD","IE0005HP3H50.USD","159938","300685","BK1583","BK1574","BK0042","BK1222","BK0239","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509276982","title":"艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509276982","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509276982?lang=zh_cn&edition=full","pubTime":"2025-02-06 20:16","pubTimestamp":1738844163,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)公告，公司截止2025年1月31日以集中竞价交易方式实施回购股份509.48万股，占公司目前总股本的1.28%，支付的总金额为9509.46万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK0042","BK0239","IE0005HP3H50.USD","300685"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503761322","title":"艾德生物(300685.SZ)获得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2503761322","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503761322?lang=zh_cn&edition=full","pubTime":"2025-01-13 16:30","pubTimestamp":1736757016,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司于近日获得由国家药品监督管理局颁发的两项《中华人民共和国医疗器械注册证》，产品名称分别为：HER-2抗体试剂(免疫组织化学)、雌激素受体抗体试剂(免疫组织化学法)。公司近期连续获得三款免疫组化诊断产品的批准：HER2(人表皮生长因子受体2)、ER(雌激素受体)和PR(孕激素受体)抗体试剂，用于指导乳腺癌患者的HER2靶向治疗和内分泌治疗。上述产品医疗器械注册证的取得，进一步丰富了公司产品布局，有利于增强公司综合竞争力，提高公司市场拓展能力，对公司未来的发展将产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1574","BK0239","BK1222","300685","09996","09997","IE0005HP3H50.USD","LU2460026573.USD","BK1583","BK0042","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495768183","title":"一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495768183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495768183?lang=zh_cn&edition=full","pubTime":"2024-12-29 10:54","pubTimestamp":1735440871,"startTime":"0","endTime":"0","summary":"12月23日至12月27日本周创业板指下跌0.22%，医疗器械板块下跌3.36%。艾德生物本周累计下跌1.67%，周总成交额3.56亿元，截至本周收盘，艾德生物股价为23.55元。评级理由主要包括：1）艾德生物是国际领先的精准医疗分子诊断龙头企业；2）伴随诊断助力肿瘤精准医疗发展；3）公司在多个癌种已建立“研发+注册+销售”护城河。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/29105446919648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2460026573.USD","09997","IE0005HP3H50.USD","BK1583","BK1574","BK1100","BK1222","BK0239","300685","159883","09996","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780806967813,"stockEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0145},{"period":"3month","weight":0.0145},{"period":"6month","weight":-0.0874},{"period":"1year","weight":-0.0304},{"period":"ytd","weight":-0.0053}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"厦门艾德生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29264人(较上一季度增加7.09%)","perCapita":"13312股","listingDate":"2017-08-02","address":"福建省厦门市海沧区鼎山路39号","registeredCapital":"39010万元","survey":" 厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服务及药物临床研究服务。公司的主要产品是检测试剂、检测服务、药物临床研究服务。凭借卓越的研发实力，公司荣获“国家企业技术中心”、“制造业单项冠军企业”、“博士后科研工作站”、“专精特新小巨人企业”等资质和荣誉，研发团队荣膺“全国工人先锋号”、研发骨干荣获“全国劳动模范”光荣称号，研发成果获评“国家科技进步二等奖”、“国家专利银奖”、“教育部科技进步一等奖”等，充分彰显了公司在行业内的技术领先地位。","listedPrice":13.86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾德生物(300685)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾德生物(300685)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾德生物,300685,艾德生物股票,艾德生物股票老虎,艾德生物股票老虎国际,艾德生物行情,艾德生物股票行情,艾德生物股价,艾德生物股市,艾德生物股票价格,艾德生物股票交易,艾德生物股票购买,艾德生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾德生物(300685)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾德生物(300685)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}